| Detected | Trial | Change |
|---|---|---|
| 2026-07-28 | NCT06369285 A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive… |
Enrollment increased: 150 -> 225 participants |
| 2026-07-28 | NCT06369285 A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive… |
date change Primary completion pushed: 2027-06-30 -> 2027-12-30 |
| 2026-07-28 | NCT06369285 A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive… |
date change Completion pushed: 2028-12-31 -> 2029-06-30 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT06095505 | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | Small Cell Lung Cancer | Recruiting |
| NCT06369285 | A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive… | Hormone Receptor Positive HER-2 Negative Breast Cancer | Recruiting |
| NCT07465757 | A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) | Small Cell Lung Cancer ( SCLC ) | Not Yet Recruiting |